Mechanistic Insights into Hybridization-Based Off-Target Activity of GalNAc-siRNA Conjugates
Nucleic Acid Therapeutics · 01.06.2025 · 35 (3) · 125-136
DOI: 10.1089/nat.2024.0090 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acid Therapeutics, online erschienen am 05.06.2025. Verfasst von Saket Agarwal und 8 weiteren Autor:innen. Beteiligte Einrichtung: Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Acetylgalactosamine, RNA, Small Interfering, Argonaute Proteins. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Nonclinical safety screening of small interfering RNAs (siRNAs) conjugated to a trivalent N -acetylgalactosamine (GalNAc) ligand is typically carried out in rats at exaggerated exposures in a repeat-dose regimen. We have previously shown that at these suprapharmacological doses, hepatotoxicity observed with a subset of GalNAc–siRNAs is largely driven by undesired RNA-induced silencing complex (RISC)-mediated antisense strand seed-based off-target activity, similar to microRNA-like regulation. However, the RISC component requirements for off-target activity of siRNAs have not been evaluated. Here, we evaluate the roles of major RISC components, AGO and TNRC6 (or GW182) proteins, in driving on- and off-target activity of GalNAc–siRNAs in hepatocytes, in vitro and in vivo . We demonstrate that knocking down AGO2, but not AGO1 or AGO4, is protective against GalNAc–siRNA-driven off-target activity and hepatotoxicity. As expected, knocking down AGO2, but not AGO1 or AGO4, reduces the on-target activity of GalNAc–siRNA. Similarly, knocking down TNRC6 paralogs, TNRC6A or TNRC6B, but not TNRC6C, is protective against off-target activity and hepatotoxicity while having minimal impact on the on-target activity of GalNAc–siRNA. These data indicate that while AGO2 is the only RISC component required for the on-target activity of GalNAc–siRNAs, the undesired off-target activity and hepatotoxicity of a subset of GalNAc–siRNAs are mediated via the RISC composed predominantly of AGO2 and TNRC6 paralogs TNRC6A and/or TNRC6B.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA.
ORCID-Profile: Saket Agarwal
Zitieren
APA
Agarwal, S., Taft, E., Gauthier, M., Darcy, J., Buckowing, K., Berman, D., Davis, W. P., Rogers, A. B., & Janas, M. M. (2025). Mechanistic Insights into Hybridization-Based Off-Target Activity of GalNAc-siRNA Conjugates. Nucleic Acid Therapeutics, 35(3), 125-136. https://doi.org/10.1089/nat.2024.0090
Vancouver
Agarwal S, Taft E, Gauthier M, Darcy J, Buckowing K, Berman D, et al. Mechanistic Insights into Hybridization-Based Off-Target Activity of GalNAc-siRNA Conjugates. Nucleic Acid Therapeutics. 2025;35(3):125-136. doi:10.1089/nat.2024.0090
BibTeX
@article{Agarwal2025,
author = {Agarwal, Saket and Taft, Elizabeth and Gauthier, Micah and Darcy, Justin and Buckowing, Kira and Berman, Daniel and Davis, Wendell P and Rogers, Arlin B and Janas, Maja M},
title = {Mechanistic Insights into Hybridization-Based Off-Target Activity of GalNAc-siRNA Conjugates},
journal = {Nucleic Acid Therapeutics},
year = {2025},
volume = {35},
number = {3},
pages = {125--136},
doi = {10.1089/nat.2024.0090}
}
EUVIMED